Dr. Mato on Managing Side Effects With Ibrutinib/Idelalisib in CLL
August 24th 2016
Anthony Mato, MD, director of the Chronic Lymphocytic Leukemia Program, University of Pennsylvania, discusses how oncologists can manage adverse events associated with ibrutinib (Imbruvica) and idelalisib (Zydelig) for the treatment of patients with chronic lymphocytic leukemia (CLL).